Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now been generated and are beginning to make progress through clinical trials. These include a suite of inhibitors targeting the KRAS(G12C) mutation commonly found in lung cancer. We investigated emergent re...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Hannah R., Ross, Sarah J., Smith, Paul D., Coulson, Judy M., Prior, Ian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555794/
https://www.ncbi.nlm.nih.gov/pubmed/36065754
http://dx.doi.org/10.1042/BCJ20220440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555794/
https://www.ncbi.nlm.nih.gov/pubmed/36065754
http://dx.doi.org/10.1042/BCJ20220440

Ejemplares similares